Furthermore, increased infiltration of CD8+ T cells expressing the chemokine receptor CXCR6—which is the receptor for CXCL16—was observed in the tumor tissues treated with iPS-ML-41BBL compared to those treated with iPS-ML (Figure 2F). This evidence concerns the gene CD8A and neoplasm.